MedWatch

Sanofi opines on Danish government's Bavarian contract: Single supplier would be a mistake

Sanofi praises Danish government despite canceling the national vaccine production tender. Even so, the company thinks it would be problematic if the state were to bet solely on Bavarian Nordic for domestic vaccine preparedness.

Manager at Sanofi Per H. Aabakken participated in the market hearing held by the Danish SSI to investigate conditions for a potential vaccine production tender, before it was cancelled. | Photo: Sanofi/PR

The Danish government should exercise caution in betting solely on a single contract with Bavarian Nordic as the solution to its ambitions of a national vaccine preparedness.

At least this is the opinion of pharmaceutical company Sanofi, which was on of the six companies courting the government for a role in the future national vaccine production. 

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs